Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
JAMA Internal Medicine, doi:10.1001/jamainternmed.2020.3596
IMPORTANCE The US is currently an epicenter of the coronavirus disease 2019 (COVID-19) pandemic, yet few national data are available on patient characteristics, treatment, and outcomes of critical illness from COVID-19. OBJECTIVES To assess factors associated with death and to examine interhospital variation in treatment and outcomes for patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study assessed 2215 adults with laboratory-confirmed COVID-19 who were admitted to intensive care units (ICUs) at 65 hospitals across the US from March 4 to April 4, 2020. EXPOSURES Patient-level data, including demographics, comorbidities, and organ dysfunction, and hospital characteristics, including number of ICU beds.
MAIN OUTCOMES AND MEASURES The primary outcome was 28-day in-hospital mortality. Multilevel logistic regression was used to evaluate factors associated with death and to examine interhospital variation in treatment and outcomes. RESULTS A total of 2215 patients (mean [SD] age, 60.5 [14.5] years; 1436 [64.8%] male; 1738 [78.5%] with at least 1 chronic comorbidity) were included in the study. At 28 days after ICU admission, 784 patients (35.4%) had died, 824 (37.2%) were discharged, and 607 (27.4%) remained hospitalized. At the end of study follow-up (median, 16 days; interquartile range, 8-28 days), 875 patients (39.5%) had died, 1203 (54.3%) were discharged, and 137 (6.2%) remained hospitalized. Factors independently associated with death included older age (Ն80 vs <40 years of age: odds ratio [OR], 11.15; 95% CI, 6.19-20.06), male sex (OR, 1.50; 95% CI, 1.19-1.90), higher body mass index (Ն40 vs <25: OR, 1.51; 95% CI, 1.01-2.25), coronary artery disease (OR, 1.47; 95% CI, 1.07-2.02), active cancer (OR, 2.15; 95% CI, 1.35-3.43), and the presence of hypoxemia (PaO 2 :FIO 2 <100 vs Ն300 mm Hg: OR, 2.94; 95% CI, 2.11-4.08), liver dysfunction (liver Sequential Organ Failure Assessment score of 2 vs 0: OR, 2.61; 95% CI, 1.30-5.25), and kidney dysfunction (renal Sequential Organ Failure Assessment score of 4 vs 0: OR, 2.43; 95% CI, 1.46-4.05) at ICU admission. Patients admitted to hospitals with fewer ICU beds had a higher risk of death (<50 vs Ն100 ICU beds: OR, 3.28; 95% CI, 2.16-4.99). Hospitals varied considerably in the risk-adjusted proportion of patients who died (range, 6.6%-80.8%) and in the percentage of patients who received hydroxychloroquine, tocilizumab, and other treatments and supportive therapies. CONCLUSIONS AND RELEVANCE This study identified demographic, clinical, and hospital-level risk factors that may be associated with death in critically ill patients with COVID-19 and can facilitate the identification of medications and supportive therapies to improve outcomes.
Author Contributions: Drs Gupta and Leaf had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the Seattle region: case series, N Engl J Med, doi:10.1056/NEJMoa2004500
Desborough, Doyle, Griffiths, Retter, Breen et al., Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom, Thromb Res, doi:10.1016/j.thromres.2020.05.049
Eg, Burton, Fort, Seoane, Hospitalization and mortality among black patients and white patients with Covid-19, N Engl J Med, doi:10.1056/NEJMsa2011686
Grasselli, Zangrillo, Zanella, None
Helms, Tacquard, Severac, CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Intensive Care Med, doi:10.1007/s00134-020-06062-x
Jehi, Ji, Milinovich, Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients, Chest. Published online, doi:10.1016/j.chest.2020.05.580
Kollias, Kyriakoulis, Dimakakos, Poulakou, Stergiou et al., Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action, Br J Haematol, doi:10.1111/bjh.16727
Lighter, Phillips, Hochman, Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission, Clin Infect Dis, doi:10.1093/cid/ciaa415
Lodigiani, Iapichino, Carenzo, Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital, Thromb Res, doi:10.1016/j.thromres.2020.04.024
Middeldorp, Coppens, Van Haaps, Incidence of venous thromboembolism in hospitalized patients with COVID-19, J Thromb Haemost. Published online, doi:10.1111/jth.14888
Mo, Xing, Xiao, Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, Clin Infect Dis, doi:10.1093/cid/ciaa270
Mohamed, Lukitsch, Torres-Ortiz, Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans, Kidney
Simonnet, Chetboun, Poissy, LICORN and the Lille COVID-19 and Obesity Study Group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity, doi:10.1002/oby.22831
Van Walraven, Bennett, Forster, Administrative database research infrequently used validated diagnostic or procedural codes, J Clin Epidemiol, doi:10.1016/j.jclinepi.2011.01.001
Vincent, Moreno, Takala, The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine, Intensive Care Med, doi:10.1007/BF01709751
Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5
Zhang, Zhang, Mi, The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis, Medicine (Baltimore), doi:10.1097/MD.0000000000015833